

March 10, 1970

Dr. William Tabor
A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia

Dear Bill,

A review of our AHR-1900 laboratory data for changes in blood glucose suggests that a hypoglycemic effect may occur in some subjects, but our data is unimpressive. An abstract of this data is enclosed.

Blood glucose (BG) measures during AHR-1900 and placebo periods are available for 6 subjects receiving AHR-1900 in dosages up to 400 mg. In L.F., J.M., A.G., and J.V., blood glucose is lower in one measure each than during the placebo period; in D.K. and C.S., blood glucose remains at the same level. In L.E., blood glucose is low but no pre-drug control is available. J.L. received AHR-1900 for 9 days only and the single BG value is not constructive. Subject M.D. did not have tests while on AHR-1900 and R.L. and E.H. received placebo only. When I asked Dr. Jones, our internist, she related the low BG readings in 3 of the patients to dosages of 120 mg or more of AHR-1900.

The other data on AHR-1900 is available for shipment, as is our report, except for the final analyses from the Biometric Laboratory. We await these to complete the publication report.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp

enc.